DGAP-News

Westhouse Medical Services Plc seeks to expand into US market by entering negotiations to acquire majority control of Sunridge International

DGAP-News: Westhouse Medical Services plc / Key word(s):
Acquisition/Capital Increase
Westhouse Medical Services Plc seeks to expand into US market by
entering negotiations to acquire majority control of Sunridge
International

08.03.2012 / 07:00

---

Westhouse Medical Services Plc seeks to expand into US market by entering
negotiations to acquire majority control of Sunridge International

Glaucoma specialist will expand Westhouse Medical Services portfolio and
allow access to US market

LONDON, UK, 8th March 2012 - Healthcare specialist Westhouse Medical
Services Plc (´Ticker Symbol 5WM´) today announces it is entering into
negotiations for the acquisition of a majority control of US listed
Sunridge International. Sunridge´s subsidiary, Ophthalmic International
Inc., has developed a glaucoma procedure called PNT, which could
revolutionise the way glaucoma is treated globally.

Westhouse Medical Services, listed on the Open Standard Section of the
Frankfurt Stock Exchange, is aggressively implementing its expansion plans,
and this acquisition will further build its medical devices subsidiary.

The majority control will also provide Westhouse Medical Services with
access to the US markets for its BreastCheck product, which is patented and
FDA approved. Currently Westhouse´s medical devices subsidiary is in the
process of bringing BreastCheck to market, a new non-invasive,
self-administered breast cancer screening device. BreastCheck is due for
launch Summer 2012.

As part of this acquisition, Westhouse aims to market PNT, the only
non-invasive, non-pharmaceutical approach that has been clinically proven
to reduce elevated intra-ocular pressure (IOP) in patients with primary
open angle Glaucoma (POAG), as well as ocular hypertension (OH). POAG
represents 95 per cent of diagnosed cases of glaucoma in Europe, the
Americas and Africa.

PNT reduces the fluid pressure in the eye, decreasing or eliminating the
need for drug therapy in a significant proportion of patients.

´As a company, we aim to create value for our investors, healthcare
providers, and patients by increasing the effectiveness, efficiency and
quality of primary healthcare, ´ comments Jack Kaye, chief executive for
Westhouse Medical Services. ´This acquisition will enable Westhouse Medical
Services to drive a step change in the treatment for over 67 million
glaucoma sufferers worldwide, whilst helping to deliver a reduction in
overall therapy costs.´

Westhouse Medical consists of two divisions - Devices and Services. This
will be the second acquisition by Westhouse´s medical devices division,
following the purchase of US and UK patents for the Profemme breast cancer
screening technology from the Battlebridge Group Limited in November 2011.
Westhouse´s other subsidiary, medical services, provides specialist
transport and ambulance services for the NHS in the UK.

WESTHOUSE MEDICAL SERVICES PLC
SYMBOL: 5WM
WKN:     A1JKH7
ISIN:      GB00B6YWDK49
SEDOL: B6YWDK4

~ends~

For press information, contact:
Jo Lee / Sian Edwards/ George Baggaley
Chameleon PR
Email: [e-mail]
Ph: [phone]

End of Corporate News

---

08.03.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP´s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

159759 08.03.2012